Three Seasons Wealth LLC Has $1.55 Million Stake in IDEXX Laboratories, Inc. $IDXX

Three Seasons Wealth LLC trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 55.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,284 shares of the company’s stock after selling 2,842 shares during the quarter. Three Seasons Wealth LLC’s holdings in IDEXX Laboratories were worth $1,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in IDXX. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the 3rd quarter valued at approximately $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories in the 4th quarter worth approximately $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $30,000. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $31,000. Finally, Armstrong Advisory Group Inc. grew its holdings in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after acquiring an additional 19 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDXX has been the topic of a number of research reports. BTIG Research dropped their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Piper Sandler dropped their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Stifel Nicolaus cut their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Barclays reduced their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $772.22.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $561.89 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The firm’s fifty day simple moving average is $625.67 and its 200 day simple moving average is $660.90. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $44.63 billion, a PE ratio of 42.99, a PEG ratio of 3.38 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the business earned $2.53 EPS. The business’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insiders Place Their Bets

In related news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last ninety days. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.